Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2015
Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functionsChi Young Ok, Zijun Y Xu-Monette, Ling Li, et al.
Blood|July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, et al.
Oncotarget|March 12, 2015
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countriesZijun Y Xu-Monette, Meifeng Tu, Kausar J Jabbar, et al.
Oncotarget|February 24, 2015
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphomaJiayu Chen, Zijun Y Xu-Monette, Lijuan Deng, et al.
Blood Advances|June 17, 2026
Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphomaZijun Y Xu-Monette, Chang Wang, Dehong Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countriesChi Young Ok, Ling Li, Zijun Y Xu-Monette, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 8, 2015
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapyZhiyu Liu, Zijun Y Xu-Monette, Xin Cao, et al.
Blood|August 29, 2013
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramZijun Y Xu-Monette, Michael B Møller, Alexander Tzankov, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 7, 2015
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOPZijun Y Xu-Monette, Bouthaina S Dabaja, Xiaoxiao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2016
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell LymphomaZijun Y Xu-Monette, Qipan Deng, Ganiraju C Manyam, et al.
Pageof 8